Press Releases for EBS

Press Releases
Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Biotech Cools Off in August But Capital Markets Remain Positive
Biotech Cools Off in August But Capital Markets Remain Positive
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2009
Emergent BioSolutions Expands Manufacturing and Development Infrastructure Through a Series of Real Estate Transactions
Emergent BioSolutions to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, 2009
Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington
Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year
Emergent BioSolutions Meets With FDA To Review Regulatory Strategy for Recombinant Anthrax Vaccine
Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern
Emergent BioSolutions Submits to FDA Development Plan Required of Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract with HHS
Emergent BioSolutions Launches BioThrax.com, an Educational Website about BioThrax (Anthrax Vaccine Adsorbed) and Anthrax Disease
Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington
Emergent BioSolutions Reports Financial Results for First Quarter 2009
Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vaccine Candidate Using EB66® Cell Line
Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX® Cell Line
Protein Sciences Announces Signing of a Forbearance Agreement With Emergent BioSolutions
New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa
Emergent BioSolutions to Release First Quarter 2009 Financial Results and Conduct a Conference Call on May 7, 2009
HHS Requires Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review
Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease
Emergent BioSolutions Reports Financial Results for Full Year 2008
Zacks Releases New Stock Picks From the +21.7% Value Strategy: Cavalier Homes, Inc., Brown Shoe Co., Inc., Emergent BioSolutions Inc., Plains Exploration & Production Co. And BioScrip Inc. - Feb 28 2009 11:55PM
Zacks Releases New Stock Picks From the +21.7% Value Strategy: Cavalier Homes, Inc., Brown Shoe Co., Inc., Emergent BioSolutions Inc., Plains Exploration & Production Co. And BioScrip Inc. - Feb 28 2009 1:12AM
Emergent BioSolutions to Webcast Presentation at the Cowen & Co. 29th Annual Health Care Conference on Tuesday, March 17, 2009
Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India
Emergent BioSolutions to Release Full Year 2008 Financial Results and Conduct a Conference Call on March 5, 2009
BenchmarkJournal.Com (Complimentary) Analyst Review for EBS, GNW, RNWK and JBHT
Emergent BioSolutions Provides Preliminary 2008 Financial Results and Guidance for 2009
Emergent BioSolutions Recognized by Security Magazine Among Best Security Organizations
Emergent BioSolutions Ends Efforts to Acquire Protein Sciences
Emergent BioSolutions Receives FDA Approval for BioThrax Supplemental Biologics License Application
Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009
Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008
Sixth Annual SOUTHWESTERN SHOWCASE Investor Conference Announces Presenting Company Webcast Schedule
Emergent BioSolutions Files Universal Shelf Registration Statement
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008
Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008
Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008
U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax(R) and Anthrax Immune Globulin under Prep Act
U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody
Emergent BioSolutions Reports Financial Results for Second Quarter 2008
Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008
Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction
Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008
Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation
Protein Sciences Responds to Emergent BioSolutions Lawsuit
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition
Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism
Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008
Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology
Emergent BioSolutions Reports Financial Results for First Quarter 2008 - Jun 1 2008 8:32PM
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology - Jun 1 2008 8:32PM
Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008
Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern